Published online Feb 2, 2016. doi: 10.5314/wjd.v5.i1.52
Peer-review started: September 2, 2015
First decision: September 29, 2015
Revised: October 30, 2015
Accepted: December 9, 2015
Article in press: December 11, 2015
Published online: February 2, 2016
Mycosis fungoides and Sèzary syndrome are the most common subtypes of cutaneous T-cell lymphomas. Even though, in early-stage disease, Mycosis fungoides commonly has a more indolent course, disease will progress in about 20% of such patients. About 30% of patients have been reported to develop advanced-stage disease and, at present, there is no cure for the disease. A number of systemic approaches have been used for advanced-stage mycosis fungoides (IIB-IV) and transformed disease. Aggressive approaches seem to be warranted in such patients. The scope of this review is the stem cell transplantation in mycosis fungoides and its leukemic variant, Sèzary syndrome.
Core tip: Some cutaneous T-cell lymphoma patients progress to advanced-stage disease or leukaemic stages. To date, there is no cure for those cases. In the last few years, several publications reported durable responses in some patients following allogeneic hematopoietic stem cell transplantation. Our aim is to define outcomes after hematopoietic stem cell transplantation for mycosis fungoides and Sèzary syndrome.